Apolipoproteins A-I and B: biosynthesis, role in the development of atherosclerosis and targets for intervention against cardiovascular disease

被引:0
|
作者
Olofsson, Sven-Olof [1 ]
Wiklund, Olov [1 ]
Boren, Jan [1 ]
机构
[1] Univ Goteborg, Wallenberg Lab, Sahlgrenska Ctr Cardiovasc & Metab Res, Gothenburg, Sweden
基金
瑞典研究理事会;
关键词
Apolipoprotein AI; atherosclerosis; cardiovascular disease;
D O I
暂无
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Apolipoprotein (apo) AI and apoB are the major apolipoproteins of high- density lipoprotein (HDL) and low-density lipoprotein (LDL), respectively. ApoB assembles the precursor of LDL, very- low- density lipoprotein (VLDL), in the liver. The assembly starts with the formation of a primordial particle, which is converted to VLDL2. The VLDL2 particle is then transferred to the Golgi apparatus and can either be secreted or converted to triglyceriderich VLDL1. We have reviewed this assembly process, the process involved in the storage of triglycerides in cytosolic lipid droplets, and the relationship between these two processes. We also briefl y discuss the formation of HDL. ApoB mediates the interaction between LDL and the arterial wall. Two regions in apoB are involved in this binding. This interaction and its role in the development of atherosclerosis are reviewed. ApoB can be used to measure the number of LDL or VLDL particles present in plasma, as there is one molecule of apoB on each particle. By contrast, the amount of cholesterol and other lipids on each particle varies under different conditions. We address the possibility of using apoAI and apoB levels to estimate the risk of development of cardiovascular diseases and to monitor intervention to treat these diseases.
引用
收藏
页码:491 / 502
页数:12
相关论文
共 33 条
  • [21] PERFORMANCE OF APO A-I AND B, AND OTHER CARDIOVASCULAR RISK FACTORS IN AZOREAN PATIENTS WITH CORONARY ARTERY DISEASE - PRELIMINARY RESULTS
    Ferin, R.
    Lima, A.
    Santos, E.
    Almeida, C.
    Pelicano, N.
    Martins, D.
    Baptista, J.
    Pavao, M. L.
    ATHEROSCLEROSIS, 2014, 235 (02) : E294 - E294
  • [22] Regression of Atherosclerosis is Characterized by Molecular Re-programming of the Transcriptome: Insights into the Identification of New Therapeutic Targets Against Cardiovascular Disease
    Feig, Jonathan E.
    Vengrenyuk, Yuliya
    Wu, Chaowei
    Aliferis, Constantin
    Statnikov, Alexander
    Garabedian, Michael J.
    Puig, Oscar
    Fisher, Edward A.
    CIRCULATION, 2012, 126 (21)
  • [23] Endothelial Expression of Scavenger Receptor Class B, Type I Protects against Development of Atherosclerosis in Mice
    Vaisman, Boris L.
    Vishnyakova, Tatyana G.
    Freeman, Lita A.
    Amar, Marcelo J.
    Demosky, Stephen J.
    Liu, Chengyu
    Stonik, John A.
    Sampson, Maureen L.
    Pryor, Milton
    Bocharov, Alexander V.
    Eggerman, Thomas L.
    Patterson, Amy P.
    Remaley, Alan T.
    BIOMED RESEARCH INTERNATIONAL, 2015, 2015
  • [24] Relation of age, the apolipoprotein B/apolipoprotein A-I ratio, and the risk of fatal myocardial infarction and implications for the primary prevention of cardiovascular disease
    Sniderman, Allan D.
    Holme, Ingar
    Aastveit, Are
    Furberg, Curt
    Walldius, Goran
    Jungner, Ingmar
    AMERICAN JOURNAL OF CARDIOLOGY, 2007, 100 (02): : 217 - 221
  • [25] Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: A case--control analysis in EPIC-Norfolk
    van der Steeg, Wim A.
    Boekholdt, S. Matthijs
    Stein, Evan A.
    El-Harchaoui, Karim
    Stroes, Erik S. G.
    Sandhu, Manjinder S.
    Wareham, Nicholas J.
    Jukema, J. Wouter
    Luben, Robert
    Zwinderman, Aeilko H.
    Kastelein, John J. P.
    Khaw, Kay-Tee
    ANNALS OF INTERNAL MEDICINE, 2007, 146 (09) : 640 - 648
  • [26] Taking action: European Atherosclerosis Society targets the United Nations Sustainable Development Goals 2030 agenda to fight atherosclerotic cardiovascular disease in Europe
    Parini, Paolo
    Frikke-Schmidt, Ruth
    Tselepis, Alexandros D.
    Moulin, Philippe
    von Eckardstein, Arnold
    Binder, Christoph J.
    Catapano, Alberico L.
    Ray, Kausik K.
    Tokgozoglu, Lale
    ATHEROSCLEROSIS, 2021, 322 : 77 - 81
  • [27] The role of IGF-I and its binding proteins in the development of type 2 diabetes and cardiovascular disease
    Ezzat, Vivienne A.
    Duncan, Edward R.
    Wheatcroft, Stephen B.
    Kearney, Mark T.
    DIABETES OBESITY & METABOLISM, 2008, 10 (03): : 198 - 211
  • [28] The role of IGF-I in the development of cardiovascular disease in type 2 diabetes mellitus: is prevention possible?
    Janssen, JAMJL
    Lamberts, SWJ
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2002, 146 (04) : 467 - 477
  • [29] Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec cardiovascular study
    Lamarche, B
    Moorjani, S
    Lupien, PJ
    Cantin, B
    Bernard, PM
    Dagenais, GR
    Despres, JP
    CIRCULATION, 1996, 94 (03) : 273 - 278
  • [30] Apo B/Apo A-I Ratio is Statistically A Better Predictor of Cardiovascular Disease (CVD) than Conventional Lipid Profile: A Study from Kathmandu Valley, Nepal
    Tamang, Hem Kumar
    Timilsina, Uddhav
    Singh, Khelanand Prasad
    Shrestha, Sanjit
    Raman, Ramendra Kumar
    Panta, Pujan
    Karna, Preeti
    Khadka, Laxmi
    Dahal, Chandika
    JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2014, 8 (02) : 34 - 36